House Asks FDA For Vytorin Study Analysis

Law360, New York (August 1, 2008, 12:00 AM EDT) -- The U.S. House Committee on Energy and Commerce sent a letter to the U.S. Food and Drug Administration Thursday asking the agency to share the results of an independent analysis of a recent study of cholesterol drug Vytorin.

The June study, known as the SEAS trial, showed that the blockbuster drug is no more effective than a placebo in treating patients with serious heart conditions.

The conclusions have been released to the FDA but have not been made more generally available, Committee Chairman John Dingell said...
To view the full article, register now.